New Chair brings decades of success to global health technology company

SOUTH RIDING, VA. – March 15, 2023 – Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of John Russell as Executive Chairman at Ultromics, a global pioneering health technology company focused on reducing the global burden of heart failure.

Russell is a well-respected leader in the medical device and diagnostic sectors of healthcare with over 30 years of experience. Prior to joining Ultromics, Russell served as the CEO and Board Member of Cardiva Medical, Inc. where he expanded the company’s commercialization of its vascular closure devices and developed the first multi-vessel closure system for cardiac ablation procedures. Russell also served as CEO of Corventis, Inc., which pioneered the industry’s first wearable and wireless cardiac monitoring patch. Earlier in his career, Russell played a key role in the development and commercial introduction of heart failure therapies and monitoring systems at Guidant and Boston Scientific.

In his new role as Executive Chairman, Russell will support the company’s commercial scaling efforts and work closely with the Ultromics team to deliver on its mission of improving patient lives through earlier and more precise diagnosis of heart failure, a life-limiting condition that affects more than 64 million people worldwide. Russell’s extensive experience in sales, marketing, business development, and research and development will be invaluable in driving the growth and success of Ultromics.

“John Russell is a highly-respected MedTech engineer, executive, and Board Member with a stellar track record of success throughout his illustrious career spanning four decades,” said Leslie Loveless, Slone Partners CEO. “His wisdom and perspectives will be very valuable to the company’s CEO and leadership team as they grow their enterprise and bring new and exciting technologies to market.”

Russell joins Ultromics following the company’s recent FDA clearance for its EchoGo® Heart Failure platform, which is the first artificial intelligence (AI) platform to detect heart failure with preserved ejection fraction (HFpEF) by connecting echocardiography with AI.

Ultromics CEO and Founder Ross Upton remarked, “I’m delighted to welcome John to our Board as Executive Chairman. His extensive experience in the MedTech and cardiovascular medical device industry will provide invaluable expertise in supporting our mission. As Ultromics continues to develop innovative technologies that utilize the power of AI to revolutionize diagnostic and treatment pathways for heart failure, John’s unique perspective and strategic insights will be instrumental in driving the company’s growth and success.”

Russell earned his bachelor’s degree in Mechanical Engineering & Materials Science from Duke University and an M.B.A. from the University of North Carolina, Chapel Hill.

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit or call 888.784.3422.

Ultromics is a pioneer in advanced heart failure detection. The ground-breaking platform, EchoGo ®, is transforming the way heart failure is diagnosed using artificial intelligence and cardiac ultrasound as a modality. The technology empowers clinicians to make precise, efficient, and accurate assessments of heart failure, leveraging the largest known heart disease outcomes dataset in echocardiography, accurately interpreting echocardiograms, and predicting cardiac outcomes. The technology has been built in collaboration with Mayo Clinic and NHS England and has over $50 million raised capital to support continued innovation with the likes of Blue Venture Fund, Optum Ventures, Oxford Science Enterprises, and GV. They are backed by the largest US health insurance firms with 4 FDA clearances. Ultromics’ mission is to stop heart failure in its tracks with its precision detection platform.